Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction

Phase 1 Completed 69 enrolled National Cancer Institute (NCI)

NaSingle-groupOpen-labelBasic science

Summary

Phase I trial to study the effectiveness of bortezomib in treating patients who have advanced cancer and kidney dysfunction. Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.

Timeline

Start: 2003-01
Primary completion: 2009-09
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bortezomib	Small molecule	—	Intravenous

Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction

Summary

Timeline

Drugs

Indications